1. Home
  2. ZLAB

as 07-11-2025 2:36pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Founded: 2013 Country:
China
China
Employees: N/A City: SHANGHAI
Market Cap: 3.6B IPO Year: 2017
Target Price: $54.28 AVG Volume (30 days): 781.8K
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.48 EPS Growth: N/A
52 Week Low/High: $16.01 - $44.34 Next Earning Date: 08-05-2025
Revenue: $418,326,000 Revenue Growth: 43.72%
Revenue Growth (this year): 44.07% Revenue Growth (next year): 49.13%

ZLAB Daily Stock ML Predictions

Stock Insider Trading Activity of Zai Lab Limited (ZLAB)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Chen Yajing ZLAB Chief Financial Officer Jun 2 '25 Sell $30.00 9,618 $288,540.00 17,429
Du Ying ZLAB Chairperson & CEO May 13 '25 Sell $28.59 96,389 $2,731,506.99 479,851
Du Ying ZLAB Chairperson & CEO May 9 '25 Sell $29.78 100,000 $2,953,307.66 479,851
Morrison Scott W ZLAB Director May 9 '25 Sell $30.05 23,799 $715,086.17 23,702

Share on Social Networks: